The investigation by Levi & Korsinsky into AstraZeneca for potential securities law violations is significant, as it follows a Chinese fraud probe involving senior executives. This could lead to legal and regulatory challenges, negatively impacting investor sentiment and potentially affecting the stock price in the short term.